John D Groarke1,2, David L Payne1, Brian Claggett1, Mandeep R Mehra1, Jingyi Gong1, Jesse Caron1, Syed S Mahmood3, Jon Hainer4, Tomas G Neilan5, Ann H Partridge2, Marcelo Di Carli4, Lee W Jones3, Anju Nohria1,2. 1. Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. 2. Adult Survivorship Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, 450 Brookline Avenue, Boston, MA 02215, USA. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. 4. Noninvasive Cardiovascular Imaging Program, Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA. 5. Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114-2696, USA.
Abstract
AIMS: The prognostic importance of post-diagnosis assessment of cardiorespiratory fitness (CRF) in cancer patients is not well established. We sought to examine the association between CRF and mortality in cancer patients. METHODS AND RESULTS: This was a single-centre cohort analysis of 1632 patients (58% male; 64 ± 12 years) with adult-onset cancer who were clinically referred for exercise treadmill testing a median of 7 [interquartile range (IQR): 3-12] years after primary diagnosis. Cardiorespiratory fitness was defined as peak metabolic equivalents (METs) achieved during standard Bruce protocol and categorized by tertiles. The association between CRF and all-cause and cause-specific mortality was assessed using multivariable Cox proportional hazard models adjusting for important covariates. Median follow-up was 4.6 (IQR: 2.6-7.0) years; a total of 411 deaths (229, 50, and 132 all-cause, cardiovascular (CV), and cancer related, respectively) occurred during this period. Compared with low CRF (range: 1.9-7.6 METs), the adjusted hazard ratio (HR) for all-cause mortality was 0.38 [95% confidence interval (CI): 0.28-0.52] for intermediate CRF (range: 7.7-10.6 METs) and 0.17 (95% CI: 0.11-0.27) for high CRF (range: 10.7-22.0 METs). The corresponding HRs were 0.40 (95% CI: 0.19-0.86) and 0.41 (95% CI: 0.16-1.05) for CV mortality and 0.40 (95% CI: 0.26-0.60) and 0.16 (95% CI: 0.09-0.28) for cancer mortality, respectively. The adjusted risk of all-cause, CV, and cancer mortality decreased by 26%, 14%, and 25%, respectively with each one MET increment in CRF. CONCLUSION: Cardiorespiratory fitness is a strong, independent predictor of all-cause, CV, and cancer mortality, even after adjustment for important clinical covariates in patients with certain cancers. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The prognostic importance of post-diagnosis assessment of cardiorespiratory fitness (CRF) in cancerpatients is not well established. We sought to examine the association between CRF and mortality in cancerpatients. METHODS AND RESULTS: This was a single-centre cohort analysis of 1632 patients (58% male; 64 ± 12 years) with adult-onset cancer who were clinically referred for exercise treadmill testing a median of 7 [interquartile range (IQR): 3-12] years after primary diagnosis. Cardiorespiratory fitness was defined as peak metabolic equivalents (METs) achieved during standard Bruce protocol and categorized by tertiles. The association between CRF and all-cause and cause-specific mortality was assessed using multivariable Cox proportional hazard models adjusting for important covariates. Median follow-up was 4.6 (IQR: 2.6-7.0) years; a total of 411 deaths (229, 50, and 132 all-cause, cardiovascular (CV), and cancer related, respectively) occurred during this period. Compared with low CRF (range: 1.9-7.6 METs), the adjusted hazard ratio (HR) for all-cause mortality was 0.38 [95% confidence interval (CI): 0.28-0.52] for intermediate CRF (range: 7.7-10.6 METs) and 0.17 (95% CI: 0.11-0.27) for high CRF (range: 10.7-22.0 METs). The corresponding HRs were 0.40 (95% CI: 0.19-0.86) and 0.41 (95% CI: 0.16-1.05) for CV mortality and 0.40 (95% CI: 0.26-0.60) and 0.16 (95% CI: 0.09-0.28) for cancer mortality, respectively. The adjusted risk of all-cause, CV, and cancer mortality decreased by 26%, 14%, and 25%, respectively with each one MET increment in CRF. CONCLUSION:Cardiorespiratory fitness is a strong, independent predictor of all-cause, CV, and cancer mortality, even after adjustment for important clinical covariates in patients with certain cancers. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Meghan Michalski; Kylie Rowed; Jessica A Lavery; Chaya S Moskowitz; Catherine Capaci; Guro Stene; Elisabeth Edvardsen; Neil D Eves; Lee W Jones; Jessica M Scott Journal: JACC CardioOncol Date: 2022-06-21
Authors: José Luis Zamorano; Christer Gottfridsson; Riccardo Asteggiano; Dan Atar; Lina Badimon; Jeroen J Bax; Daniela Cardinale; Antonella Cardone; Elizabeth A M Feijen; Péter Ferdinandy; Teresa López-Fernández; Chris P Gale; John H Maduro; Javid Moslehi; Torbjørn Omland; Juan Carlos Plana Gomez; Jessica Scott; Thomas M Suter; Giorgio Minotti Journal: Eur J Heart Fail Date: 2020-10-02 Impact factor: 15.534
Authors: Michael R Harrison; Paul G Davis; Michel G Khouri; David B Bartlett; Rajan T Gupta; Andrew J Armstrong; Megan A McNamara; Tian Zhang; Monika Anand; Kelly Onyenwoke; Sara Edwardson; Danielle Craig; Meghan Michalski; Yuan Wu; Taofik Oyekunle; Brian Coyne; Aubrie Coburn; Lee W Jones; Daniel J George Journal: Prostate Cancer Prostatic Dis Date: 2022-03-10 Impact factor: 5.554
Authors: Hawley E Kunz; John D Port; Kenton R Kaufman; Aminah Jatoi; Corey R Hart; Kevin J Gries; Ian R Lanza; Rajiv Kumar Journal: J Appl Physiol (1985) Date: 2021-12-23
Authors: Alis Bonsignore; Thomas H Marwick; Scott C Adams; Babitha Thampinathan; Emily Somerset; Eitan Amir; Mike Walker; Husam Abdel-Qadir; C Anne Koch; Heather J Ross; Anna Woo; Bernd J Wintersperger; Mark J Haykowsky; Paaladinesh Thavendiranathan Journal: JACC CardioOncol Date: 2021-11-16
Authors: Raheel Rizwan; Kimberlee Gauvreau; Cheryl Vinograd; Jessica M Yamada; Christina Mangano; Andrea K Ng; Mark E Alexander; Ming Hui Chen Journal: JACC CardioOncol Date: 2021-06-15
Authors: Scott C Adams; Jennifer Herman; Iliana C Lega; Laura Mitchell; David Hodgson; Kim Edelstein; Lois B Travis; Catherine M Sabiston; Paaladinesh Thavendiranathan; Abha A Gupta Journal: JNCI Cancer Spectr Date: 2020-10-28